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Abstract
We have already shown that cytokine cocktails (IL-1ß, IL-
3, IL-6, SCF, GM-CSF) and/or lymphokine-activated killer
(LAK) cells can reduce the amounts of clonal, CD34-posi-
tive mononuclear bone marrow cells (BM-MNC) in acute
myeloid leukemia (AML). In addition, the influence of
those cocktails and/or LAK cells on the clonogenic poten-
tial of AML BM-MNC was investigated. BM colonies cul-
tured in agar during different stages of the disease were
immunophenotyped in situ: 17 patients at diagnosis, 14
patients in complete remission, 8 patients at relapse, 8
healthy donors. A significant reduction in leukemic cells
and colonies positive for CD34 after in vitro culture of
BM-MNC with cytokine cocktails was achieved with all
samples obtained at diagnosis (n = 8, p ! 0.01), in 6 of 8
cases in complete remission but only in 2 of 6 cases at
relapse. Cytokine cocktails stimulated granulopoiesis as
well as B and T lymphopoiesis. Colonies with leukemic
phenotype could never be detected in healthy BM. A sig-
nificant reduction in leukemic colonies was achieved by
coculture of BM-MNC (uncultured or cytokine precul-
tured) with autologous LAK cells in all 4 cases at diagno-
sis and in 1 case at relapse. An additive effect of in vitro
cytokine preincubation of BM samples on the leukemia-
reducing effect of LAK cells could be demonstrated in all
samples studied (p ! 0.001; diagnosis: n = 10, relapse: n =
3, complete remission: n = 7). Patients had a better prog-
nosis if CD34-positive colonies in AML could be reduced
by cytokine incubation (p = 0.03) or coculture with autol-
ogous LAK cells in vitro (p = 0.04). Our data show that
cytokines as well as LAK cells alone and in combination
can reduce, however not eliminate clonogenic AML cells.
Such mechanisms might be responsible for maintaining
stable remissions in AML.
Copyright © 2001 S. Karger AG, Basel
Introduction
Acute myeloid leukemia (AML) results in an accumu-
lation of leukemic blasts through clonal proliferation from
one abnormal progenitor cell. Clonal cell populations can
be identified by cytogenetics, polymerase chain reaction
and Southern blot analyses [1, 2]. Leukemic cell popula-



















   
   
   
   
   
   
   
   
   
   
   





















210 Acta Haematol 2001;105:209–221 Walburg Braun/Gerhartz/Schmetzer
different antibodies [3]. At colony level, leukemic colo-
nies can be distinguished from nonleukemic colonies by
culture of bone marrow mononuclear cells (BM-MNC) in
a clonogenic assay with consecutive immunophenotyping
in situ [4]. About 70% of patients with AML in complete
remission relapse within 2 years. Therefore residual leu-
kemic cells must have survived [5]. In patients who do not
relapse, mechanisms must exist which inhibit or even
eradicate those leukemic cells. Besides cellular mecha-
nisms, several soluble factors and cytokines seem to play a
role in the suppression of leukemic cells. Up to now, ani-
mals have been treated by several cytokines like IL-2 or
interferon-· in order to find tumoricidal factors or to test
the efficiency of different substances in restoring normal
hematopoietic bone marrow cells. Moreover, IL-3, GM-
CSF, or G-CSF are reported to regulate the proliferation
of leukemic cells [6–8]. Preclinical data of others and our-
selves show a positive synergistic effect of SCF, GM-CSF,
IL-1ß, IL-3, IL-6 and EPO on the proliferation of hemato-
poietic progenitor cells; moreover we could already dem-
onstrate a reduction in CD34-positive, clonal cells in
patients with AML [9, 10]. Cytotoxic mechanisms, me-
diated for example by natural killer (NK) or LAK cells,
are known to suppress leukemic growth in vivo or in vitro,
as already shown by others and ourselves [11, 12]. How-
ever, the influence of cytokines and/or LAK cells on the
clonogenic potential of AML cells in vitro with respect to
an influence on clonal CD34-positive cells has to be evalu-
ated. We investigated the influence of LAK cells and of
different combinations of growth factors on the survival
of leukemic and normal cell colonies in vitro using
untreated and cytokine-precultured BM-MNC of AML
patients at diagnosis or in the course of the disease. Leu-
kemic cell load in BM-MNC was evaluated by immuno-
phenotyping of single cells (flow cytometry) and cell colo-
nies after agar culture (enzyme immunoassay), and the
proportion of clonal cells was evaluated by Southern blot
analysis and densitometry. The clinical relevance of our
in vitro studies was evaluated by survival analyses of
patient groups formed according to response to in vitro
cytokine treatment and/or LAK cell treatment.
Materials and Methods
Patients
Patients (mean age 49 years, male to female ratio 1.17:1) under-
went cytological and cytochemical tests on diagnosis (17 patients), in
complete remission (14) and at relapse (8 patients). Classification
according to FAB criteria was as follows: 3 patients with AML-M0, 3
with AML-M1, 9 with AML-M2, 9 with AML-M4, 5 with AML-M5
and 10 with unknown FAB type. All the patients were included in the
study at initial therapy and none had been previously treated.
Patients were treated according to approved therapy standards.
Complete remission was defined according to the criteria of the Can-
cer and Leukemia Groups (CALGB) when BM was normocellular,
contained less than 5% blast, and at least 1.5 ! 109/l neutrophil gran-
ulocytes in peripheral blood (PB) and at least 100 ! 109/l platelets
[6]. Relapse was diagnosed morphologically when the BM contained
more than 5% leukemic blasts, or when leukemic cell infiltration
occurred at any other site. BM cells obtained from 8 healthy donors
served as controls.
Cell Preparation
BM cells were obtained by aspiration from the patients’ posterior
iliac crest after informed consent and collected in preservative-free
heparin. MNC were obtained from BM cells by Ficoll (density 1.077;
Seromed) density gradient centrifugation and washed in Hanks’ bal-
anced salt solution with NaHCO3 (Seromed).
Culture of BM Cells with Cytokine Cocktails
BM-MNC of AML patients obtained at different times in the
course of their disease and BM-MNC from healthy BM donors were
cultured (1.0 ! 106 cells/ml media) in cytokine-containing media for
14 days at 37°C and 5% CO2 in a humidified atmosphere. We used
two different cytokine cocktails [7]:
(1) Cytok 1: IL-1ß (10 ng/ml, Boehringer Ingelheim) + IL-3 (20
U/ml, Novartis) + IL-6 (100 U/ml, Novartis) + EPO (1 U/ml, Boeh-
ringer Mannheim) + SCF (100 ng/ml, Amgen) + GM-CSF (100 ng/
ml, Novartis) in Iscove’s modified Dulbecco’s medium (ISC, Gib-
coBRL) and 20% fetal calf serum (FCS, HyClone).
(2) Cytok 2: had the same composition as Cytok 1 but without
GM-CSF.
(3) ISC/FCS: control medium without added cytokines in ISC
containing 20% FCS.
Culture of LAK Cells and Coculture with Autologous BM Cells
We performed coculture experiments in order to test the antileu-
kemic effect of LAK cells on autologous BM cells. LAK cells were
obtained after 14 days of culture of 0.5–1.0 ! 106 PB cells/ml in the
presence of 1,000 U/ml IL-2 (Cetus Ltd., Ratingen, Germany) in
LAK medium (69% ISC, GibcoBRL), 15% equine serum (HyClone),
5% FCS (HyClone), 1% penicillin-streptomycin (GibcoBRL) [12].
After 2 weeks those cells were analyzed for the expression of antigens
like CD5, CD56, CD16, CD8 and CD25 typical for LAK cells [12,
13]. BM cells from AML patients were aspirated at different stages of
the disease and from healthy BM donors. BM-MNC were (a) either
frozen in liquid nitrogen by a computer-driven freezing procedure
and thawed after 14 days for coculture with LAK cells or (b) were
cultured for 14 days in Cytok 1, Cytok 2 or ISC/FCS as a control and
afterwards added to autologous LAK cells [10]. LAK and BM cells
were mixed in a proportion of 5:1. After 4 h, the cell mixtures were
mixed with agar, plated on special slides (BioRad) and stimulated by
GM-CSF (500 U/ml) for a 7-day colony assay [4]. In this colony assay
LAK cells formed colonies under the influence of GM-CSF. There-
fore the proportions of leukemic colony forming units (CFUs) under
the influence of LAK cells in a 5:1 mixture with autologous BM cells
had to be calculated according to the following formula:
(tcp
(1)) – (5/6 tLAKp
(2))
(tca
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where tcp = total number of colonies positive for an antibody; tca =
total number of all colonies counted; tLAKp = total number of LAK
colonies positive for an antibody; tLAKa = total number of all LAK
colonies counted; (1) = colony numbers obtained in the LAK/BM
coculture, and (2) = colony number obtained in the LAK control cul-
ture.
Immunophenotyping of Agar Colonies in situ
To study the viability of BM-MNC as well as the influence of
cytokines and autologous LAK cells on leukemic colonies, we cul-
tured mononuclear cells for 7 days in a miniaturized culture assay
directly on sterilized and specially prepared slides obtained from Bio-
Rad as previously described [4]. 3 ! 104 BM-MNC were suspended
in 20 Ìl ISC/FCS and 0.25% agar agar (Fluka, Bio Chemika). After
jelling at 37°C, 40 Ìl GM-CSF medium (500 U/ml (Novartis) in ISC/
FCS) was layered on top of each plug. After 7 days of culture, colony
counts were calculated. Moreover, immunologically stained colonies
were counted after in situ incubation with a panel of different anti-
bodies [4]. The total cell and colony counts before and after 14 days
of cytokine incubation (Cytok 1, Cytok 2 or ISC/FCS as a control) or
LAK cell treatment were evaluated to estimate the reductive effect
on leukemic colonies as well as the proliferation-stimulating effect of
those cytokine cocktails and LAK cells. The following unconjugated
antibodies were used: CD34 (HPCA-I, Becton-Dickinson), CD20
(B 1, Coulter), CD13 (My 7, Coulter), CD15 (Leu M1, Becton-Dick-
inson), HLA-DR (Becton-Dickinson).
Surface Marker Analyses
Flow cytometric analyses were performed on uncultured and cul-
tured BM-MNC in order to estimate the percentage of blast cells
(positive for CD34), granulocytes (positive for CD15 and CDw65), T
cells (positive for CD3) and B cells (positive for CD19 and CD20) [3,
4]. Antibodies conjugated with fluorescent dyes – phycoerythrin (PE)
or fluorescein isothiocyanate (FITC) – were used: CD34 (class III
clone 581, PE-labeled; Immunotech), CD15 (FITC or PE-labeled;
Sigma), CDw65 (FITC-labeled; Ortho), CD19 (PE-labeled; Ortho),
CD20 (PE-labeled, Dako) or CD3 (FITC-labeled; Ortho). Blast phe-
notypes at diagnosis were regularly evaluated using a panel of differ-
ent leukocyte antibodies in combination according to consensus pro-
tocols [3]. In the further course of AML a patient’s typical antibody
combinations – including CD34 antibodies in combination with pan-
myeloid (e.g. CD13, CD33) and pan-leukocyte antibodies (CD45) –
were used to quantify CD34-positive cells. To avoid unspecific or
epitope class-specific variations of antibody binding the same CD34
antibodies of the same company were always used. Analyses were
performed on a flow cytometer (Cytoron Absolut, Ortho Diagnostic
Systems). Data were evaluated using a special software (Immuno-
count 2) from Ortho Diagnostic Systems. The percentage increase or
decrease of cells positive for the antibodies mentioned above before
and after the cytokine treatment was calculated.
Statistics
Statistical tests (log-rank test, Mann-Whitney U test, repeated-
measures Anova) were performed on a personal computer by a spe-
cial software (Statistica 4.5, StatSoft Inc. 1993). All tests used were
two-tailed. Differences were considered significant for p ! 0.05. For
survival analyses, patients were assessed at the time of BM transplan-
tation and the data expressed by a Kaplan-Meier plot.
Results
Clonogenic Potential and Cellular Composition of
Uncultured or Precultured BM-MNC from AML
Patients at Different Stages of the Disease
Combinations of SCF with several cytokines are rec-
ommended to enrich hematopoietic stem cells [7]. The
influence of those cytokine cocktails on clonogenic leu-
kemic or healthy BM cells was studied. BM-MNC of
AML patients at different stages of the disease were cul-
tured in Cytok 1 (containing GM-CSF), Cytok 2 or ISC/
FCS being used as controls. The clonogenic leukemic
potential in BM samples (before and after cytokine cul-
ture) was evaluated after 7 days of culture in agar in the
presence of GM-CSF. Moreover, cells were immunophe-
notyped before and after cytokine culture. In total, BM
samples of 39 AML patients were studied: 17 at diagnosis,
8 at relapse and 14 in complete remission. BM-MNC
from 8 healthy BM donors served as controls. The per-
centage of BM colonies of uncultured or precultured (with
Cytok 1, Cytok 2 or ISC/FCS) BM cells positive for their
respective antibodies are given.
Proportions of Leukemic and Nonleukemic Uncultured
BM Cells or BM Colonies after 7 Days of GM-CSF
Culture (table 1)
Proportions of undifferentiated (CD34-positive) or
granulocytic (CD15-positive) cells or colonies after 7 days
of culture in GM-CSF were evaluated in order to estimate
the leukemic potential in BM samples obtained at diagno-
sis, at relapse, in complete remission or in control sam-
ples. On average, 54.4 B 15.8, 13.3 B 2.3, 7.0 B 2.5 and
4.3 B 0.9% CD34-positive cells could be detected in BM
samples obtained at diagnosis, at relapse, in complete
remission or in controls, respectively (table 1). At the
same time, 35.3 B 13.5, 33.2 B 9.3, 56.5 B 8.2 and 62.3
B 6.4% CD15-positive cells could be detected at diagno-
sis, at relapse, in complete remission or in controls,
respectively (table 1). After 7 days of culture of BM-MNC
in the presence of GM-CSF, 30.2 B 7.4, 7.6 B 1.7, 2.5 B
1.5 and 0% CD34-positive colonies could be detected in
samples obtained at diagnosis, at relapse, in complete
remission or in controls, respectively (table 1). At the
same time, 26.3 B 7.9, 22.6 B 7.2, 39.8 B 11.2 and 52.4
B 6.3% CD15-positive colonies could be detected at diag-
nosis, at relapse, in complete remission or in controls (ta-
ble 1). Proportions of CD15-positive cells or colonies
were significantly higher in BM samples obtained from
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Table 1. Proportions of CD34+ or CD15+ BM cells or colonies (in parentheses) after 7 day of culture with GM-CSF
FAB
type
































45 (36) 42 (21) M4 12 (11) 27 (14) M5a 10 (2) 62 (51) 1 5 (0) 75 (49)
M5 41 (27) 23 (28) M2 15 (8) 32 (36) M5b 10 (3) 42 (n.d.) 2 3 (0) 65 (54)
M2 55 (33) 15 (34) M1 15 (6) 19 (16) M2 3 (0) 70 (44) 3 5 (0) 65 (46)
M2 60 (21) 35 (36) M0 16 (7) 43 (19) M4 6 (3) 60 (38) 4 3 (0) 63 (64)
M2 70 (29) 20 (45) M2 12 (9) 43 (23) n.d. 6 (n.d.) 46 (59) 5 4 (0) 57 (51)
M0 87 (48) 40 (34) M4 10 (7) 35 (21) M2 7 (3) 65 (20) 6 4 (0) 57 (58)
M0 80 (33) 18 (29) n.d. n.d. (6) n.d.(22) M1 10 (5) 52 (26) 7 5 (0) 61 (45)
M2baso 54 (35) 48 (21) n.d. n.d. (7) n.d. (30) M4 4 (4) 60 (39) 8 5 (0) 55 (52)
M4 35 (24) 47 (20) M5b 7 (3) 57 (32)
M5b 50 (44) 37 (19) M4 5 (2) 52 (28)
n.d. 37 (26) 44 (24) M4 9 (3) 55 (49)
M2 60 (22) 35 (21) n.d. n.d. (1) n.d. (46)
M4 41 (29) 63 (24) n.d. n.d. (0) n.d. (48)
M4 47 (25) 27 (15) n.d. n.d. (3) n.d. (37)
n.d. n.d. (31) n.d. (34)
n.d. n.d. (28) n.d. (21)
n.d. n.d. (23) n.d. (21)
DIA = Diagnosis; REL = relapse; CR = complete remission; n.d. = not determined.




AML at DIA (n = 10)
CD34+ cells (%) or colonies after in
vitro culture with ...
Cytok 1 Cytok 2 ISC/FCS
FAB
type
AML at REL (n = 6)
CD34+ cells (%) or colonies after
in vitro culture with ...
Cytok 1 Cytok 2 ISC/FCS
FAB
type
AML in CR (n = 10)
CD34+ cells (%) or colonies after in
vitro culture with ...
Cytok 1 Cytok 2 ISC/FCS
n Healthy controls (n = 8)
CD34+ cells (%) or colonies after in
vitro culture with ...
Cytok 1 Cytok 2 ISC/FCS
–62 (–54) n.d. (n.d.) –49 (n.d.) M4 +25 (–20) n.d. (n.d.) +67 (–6) M5a +40 (–15) +40 (n.d.) +60 (+8) 1 c100 (B0) n.d. (n.d.) c20 (B0)
M5 –49 (–50) n.d. (n.d.) –49 (–21) M2 +40 (–18) n.d. (n.d.) n.d. (+2) M5b n.d. (–4) n.d. (n.d.) n.d. (+14) 2 c100 (B0) n.d. (B0) c33 (B0)
M2 n.d. (–50) n.d. (n.d.) n.d. (–18) M1 +12 (+4) +12 (n.d.) +18 (+6) M2 n.d. (–8) n.d. (n.d.) n.d. (n.d.) 3 B0 (B0) n.d. (B0) B0 (B0)
M2 n.d. (–46) n.d. (–36) n.d. (–16) M0 –57 (–8) –24 (n.d.) –11 (–6) M4 –33 (–24) n.d. (n.d.) +17 (+4) 4 c233 (B0) +133 (B0) c67 (B0)
M2 –74 (–43) –64 (–37) –57 (n.d.) M2 –17 (–37) +32 (–14) +48 (–6) M2 –29 (–38) n.d. (–35) –19 (–30) 5 c275 (B0) +200 (B0) c125 (B0)
M0 –75 (–53) –67 (–51) –66 (–41) M4 +45 (–16) +55 (–10) +73 (–9) M1 –56 (–57) –67 (n.d.) –50 (–38) 6 c275 (B0) +170 (B0) c150 (B0)
M0 –64 (–55) –61 (–51) –49 (–37) M4 –75 (–42) –50 (–34) B0 (–4) 7 c300 (B0) +200 (B0) c180 (B0)
M2baso –78 (–57) –63 (–48) –59 (–27) M5b +27 (–22) B0 (n.d.) +67 (+17) 8 c300 (B0) +260 (B0) c220 (B0)
M5b –57 (–44) –57 (n.d.) –51 (–20) M4 –80 (–29) n.d. (–8) n.d. (+13)
M2 –37 (–43) –28 (–28) –27 (–17) M4 –44 (–47) n.d. (n.d.) n.d. (n.d.)
DIA = Diagnosis; REL = relapse; CR = complete remission; n.d. = not determined; + = increase of positive cells or colonies (%) compared to results with untreated BM-MNC; – =
decrease of positive cells or colonies (%) compared to results with untreated BM-MNC.
obtained at diagnosis or at relapse (p ! 0.005). Otherwise,
proportions of CD34-positive cells and colonies were sig-
nificantly higher in BM samples obtained at diagnosis
than at relapse or in complete remission (p ! 0.05). Pro-
portions of B or T cells were not different in the groups
compared (data not shown). Whereas low amounts of
CD34-positive cells could be detected in control samples,
no CD34-positive colonies could be grown from control
samples (table 1). A high correlation between percentages
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Fig. 1. Influence of cytokines on BM-MNC. Percentages of CD34- or CD15-positive colonies before and after 14 days
of culture in Cytok 1, Cytok 2 or ISC/FCS. a AML at diagnosis (n = 10). b AML at relapse (n = 6). c AML in complete
remission (n = 10). d BM from healthy donors (n = 8).
30, r = 0.89, p ! 0.0001, data not shown) as well as
between CD15-positive cells and colonies could be dem-
onstrated (n = 38, r = 0.50, p ! 0.005, data not shown),
proving the clonogenic results.
Influence of Cytokine Cocktails on Proportions of
Leukemic and Nonleukemic BM Cells and BM
Colonies (table 2, fig. 1)
Results of Diagnosis of AML (table 2, fig. 1a). At diag-
nosis (n = 10), a significant reduction in CD34-positive
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0.01) was achieved by 14 days of incubation of BM-MNC
in Cytok 1 or Cytok 2 or ISC/FCS as compared to BM-
MNC not pretreated by cytokines (table 2, fig. 1a). In all
BM samples a reduction of at least 27–78% CD34-posi-
tive cells as well as of 16–57% CD34-positive colonies was
achieved at diagnosis (table 2). Cell culture in cytokine-
containing medium resulted in significantly elevated
granulocyte counts (p ! 0.001, data not shown) or granu-
locyte colonies (p ! 0.001, fig. 1a). Moreover, cytokine
cocktails stimulated lymphopoietic B and T cells (p !
0.005, data not shown). In summary, our data show that
compared to control cultures (ISC/FCS), cytokines in the
culture cocktails (Cytok 1, Cytok 2) significantly in-
creased the described effects (p ! 0.05, table 2, fig. 1a).
Results at Relapse of AML (table 2, fig. 1b). In contrast
to the results at diagnosis, at relapse (n = 6) no significant
reduction of CD34-positive cells or colonies could be
achieved by culture of BM-MNC with cytokine cocktails
(table 2, fig. 1b): a reduction in CD34-positive cells in
cytokine-containing medium of at least 57% was seen in
only 2 of 6 cases (table 2). In the other cases, CD34-posi-
tive cells expanded by 55% under the influence of cyto-
kines (table 2). The amounts of CD34-positive colonies
could be reduced by cytokine cocktails in 5 of 6 cases by
Cytok 1, in 2 of 2 cases by Cytok 2, but only in 4 of 6 cases
by ISC/FCS. Cytokine cocktails stimulated granulopoiesis
(p ! 0.05, fig. 1b) as well as B and T lymphopoiesis com-
pared to control cultures without added cytokines (p !
0.01, data not shown). Again the culture cocktails in-
creased the effects demonstrated compared to control cul-
tures with ISC/FCS (table 2, fig. 1b).
Results in Complete Remission of AML (table 2,
fig. 1c). In complete remission (n = 10), CD34-positive
cells on average remained more or less the same after
incubation with cytokine cocktails (table 2, fig. 1c). A
reduction in CD34-positive cells was achieved in 6 of 8
cases studied by Cytok 1, in 2 of 4 cases by Cytok 2 and in
2 of 6 cases by ISC/FCS (table 2). At the colony level,
amounts of CD34-positive agar colonies were reduced by
Cytok 1 and Cytok 2 by at least 4–57% in 10 of 10 cases
(table 2). However, in only 3 of 8 cases cultured with ISC/
FCS could a reduction of CD34-positive colonies be dem-
onstrated (table 2). A stimulating effect of cytokine cock-
tails on granulopoiesis (p ! 0.01, fig. 1c) as well as on B
and T lymphopoiesis could be seen (p ! 0.05, data not
shown). Again cytokines in the culture medium increased
the described effects compared to ISC/FCS (table 2,
fig. 1c).
Results in Healthy BM Samples (table 2, fig. 1d). In 7
of 8 healthy BM samples a significant increase in CD34-
positive cells (p ! 0.05) (table 2), of granulocytes as well as
of B and T cells (data not shown) could be demonstrated
following incubation of BM-MNC with cytokine cock-
tails. CD34-positive colonies in agar could not be detected
in any culture condition (table 2). Without cytokines add-
ed to the culture medium, a significant decrease of CD15-
positive colonies was found (p ! 0.001, fig. 1d). An
increase in granulopoiesis as well as in B and T lympho-
poiesis was observed at single-cell level (data not shown)
following incubation with cytokine cocktails.
As very few BM samples were studied in parallel after
Cytok 1 and Cytok 2 culture, a statistical comparison of
cases divided in different stage groups was not possible.
When all AML cases (cases at diagnosis, at relapse and in
complete remission pooled), that were studied in parallel
with Cytok 1 and Cytok 2 were compared, a significantly
higher reduction in CD34-positive cells could be demon-
strated with (Cytok 1) than without GM-CSF (Cytok 2)
(p ! 0.05; n = 14). At colony level, a better, however not
significant, reduction in CD34-positive colonies with Cy-
tok 1 than with Cytok 2 could be demonstrated.
In summary, our data show that cytokine cocktails
(Cytok 1) led to a reduction in CD34-positive cells and
agar colonies in all 8 AML cases studied at diagnosis, in 2
of 6 cases studied at relapse and in 6 of 8 cases studied in
complete remission. In 7 of 8 healthy BM samples, CD34-
positive cell proportions were increased; however, CD34-
positive agar colonies could not be detected. These data
prove that CD34-positive cells in AML are clonal cells,
whereas CD34-positive cells from healthy donors grown
in cytokine cocktails (Cytok 1, 2) are healthy, nonclonal
stem cells.
Control Experiments
Whenever possible, cell counts and cloning efficiency
were measured before and after cytokine treatment. The
absolute cell counts were increased by Cytok 1 and Cytok
2, but not by ISC/FCS treatment: in normal BM samples,
the absolute cell counts increased by 79.3 B 29.1% (Cy-
tok 1) or 84.8 B 28.6% (Cytok 2), whereas in BM-MNC
obtained at diagnosis of AML cell counts increased by
47.0 B 25.3% or 49.9 B 24.6%, by 95.6 B 36.9% or
130.3 B 56.9% at relapse and by 56.1 B 24.0% or 82.8 B
30.3% in complete remission. However, ISC/FCS led to a
decrease in cell counts by 39.4 B 12.6% in healthy BM
samples, by 20.8 B 14.4% at diagnosis and by 39.2 B
9.5% in complete remission. At relapse, cell counts in-
creased by 8.0 B 20.0%. The viability of BM-MNC was
not influenced by Cytok 1, Cytok 2 or ISC/FCS treatment:
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Fig. 2. Survival probability of AML patients at diagnosis; the proportions of CD34-positive BM cells (a; n = 12) or
BM colonies (b; n = 10) could be reduced by more (1) or less (2) than 50% by Cytok 1 in vitro.
treatment were more or less the same as compared to
counts after treatment (data not shown).
In conclusion, cytokine treatments as described here
have no negative influence on cell growth or viability of
BM-MNC. Addition of cytokines (Cytok 1, Cytok 2) to
the control medium (ISC/FCS) resulted in an increase in
the absolute single cell and colony counts.
Prognostic Value of Cytokine Treatments in vitro
(fig. 2)
Statistical evaluation of our data revealed that AML
patients studied at diagnosis survived longer, if CD34-
positive cells (p = 0.04, fig. 2a) or CD34-positive colonies
(p = 0.03, fig. 2b) grown from BM-MNC in cytokine-con-
taining medium (Cytok 1) could be reduced by more than
50% in vitro. No significant differences could be found
when other cut-off points were chosen (data not shown).
Relapse-free survival times were significantly longer in
those patients in whom a reduction of CD34-positive cells
or CD34-positive colonies could be demonstrated in vitro
(p = 0.04, data not shown). At the clonal level, the proba-
bility to achieve or stay in complete remission for a longer
time was significantly higher in those patients studied at
diagnosis or at relapse in whose BM samples a reduction
in the amount of rearranged DNA could be achieved by
culture of BM-MNC in Cytok 1 in vitro (p = 0.02, data not
shown). Hematological parameters such as white blood
cells, hemoglobin values or proportions of granulocytes, B
or T cells or CD34-positive cells were not different in the
groups compared before cytokine treatment (data not
shown).
In summary, our results have clinical significance:
patients had a better prognosis if CD34-positive cells or
colonies or amounts of clonal DNA could be reduced by
Cytok 1 in vitro.
Cytotoxic Effect of Autologous LAK Cells on
Uncultured or Precultured Leukemic or Nonleukemic
BM Cells and BM Colonies (table 3, fig. 3)
The potential cytotoxic effect of LAK cells on un-
treated or cytokine-precultured leukemic BM cells was
evaluated after coculture. Proportions of CD34-positive
BM agar colonies before and after coculture with LAK
cells were evaluated and compared.
Influence of LAK Cells on Uncultured (Thawed)
AML-BM Cells (table 3)
Coculture of LAK cells with untreated BM-MNC from
AML patients at diagnosis resulted in a reduction in
CD34-positive colonies (by 16–40%, table 3) as well as in
CD15-positive colonies (by 3–5%) in all 4 cases examined
(data not shown). In the case studied at relapse, a reduc-
tion in CD34-positive colonies by 14% could be demon-
strated (table 3). No experiments were performed with
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Table 3. Influence of autologous LAK cells on uncultured or cytokine precultured CD34-positive BM colonies
FAB
type




Cytok 1 Cytok 2 ISC/FCS
FAB
type




Cytok 1 Cytok 2 ISC/FCS
FAB
type




Cytok 1 Cytok 2 ISC/FCS
n.d. –22 n.d. –21 M4 n.d. n.d. n.d. –21 M5a n.d. –25 n.d. B0
M5 n.d. –30 n.d. –24 M2 n.d. –17 n.d. –13 M5b n.d. –20 n.d. c1
M2 n.d. –26 –12 –9 M1 n.d. –25 –20 –8 M4 n.d. –51 n.d. U28
M2 n.d. –9 n.d. –4 M2 –14 –25 –18 –16 M2 n.d. –2 n.d. c11
M2 –24 –37 –33 n.d. M4 n.d. –28 n.d. B0 
M0 –16 –31 –26 –25 M5b n.d. –16 n.d. c24
M0 –17 –10 –10 –5 M4 n.d. –23 –14 U13
M2baso –40 –31 –26 –16
M5b n.d. –28 n.d. –6
M2 n.d. –29 n.d. –13
n.d. = Not determined; uncult. = uncultured; + = increase of positive colonies (%) compared to results before LAK/BM coculture; – = decrease of positive
colonies (%) compared to results before LAK/BM coculture.
Influence of LAK Cells on Cytokine-Precultured
AML-BM Cells (table 3, fig. 3)
The influence of LAK cells on cytokine-pretreated BM
cells was studied. After coculture of LAK cells with BM-
MNC, the amounts of CD34-positive colonies were evalu-
ated after an additional 7 days of culture in agar under
GM-CSF stimulation to estimate the leukemic potential
of the cocultured cell mixture.
Results at Diagnosis of AML (table 3, fig. 3a). At diag-
nosis, a significant reduction of CD34-positive colonies
(p ! 0.001) and an increase of CD15-positive granulocytic
colonies (p ! 0.001) could be achieved by coculture of
LAK cells with cytokine-pretreated BM-MNC (table 3,
fig. 3a). In all BM samples (n = 10) studied at diagnosis, a
reduction in CD34-positive colonies by at least 4–37%
could be achieved (table 3). The highest reduction of leu-
kemic CD34-positive colonies could be achieved if BM-
MNC were precultured with Cytok 1 (table 3, fig. 3a).
Results at Relapse of AML (table 3, fig. 3b). LAK cell
coculture of cytokine-pretreated BM-MNC from AML
patients at relapse resulted in a minimal, not significant,
reduction by 8–25% of CD34-positive colonies (table 3).
If BM-MNC were precultured with Cytok 1 and then
cocultured with LAK cells, an increase in CD15-positive
granulocyte colonies could be seen (p ! 0.05, fig. 3b).
Without cytokines in the culture medium (ISC/FCS), the
percentage of granulocytic colonies decreased (p ! 0.05,
fig. 3b).
Results in Complete Remission of AML (table 3,
fig. 3c). LAK cell coculture of cytokine-pretreated BM-
MNC (Cytok 1) from AML patients in complete remis-
sion resulted in a reduction by 2–51% of CD34-positive
colonies (table 3). Without added cytokines (ISC/FCS)
the amounts of CD34-positive colonies could be de-
creased by LAK cells in only 2 of 7 patients (table 3).
Coculture of LAK cells and BM cells after Cytok 1 prein-
cubation of BM-MNC resulted in elevated CD15-positive
granulocyte colonies (p ! 0.05, fig. 3c), whereas without
cytokine preincubation the amounts of CD15-positive
colonies decreased (ISC/FCS, p ! 0.05, fig. 3c).
Results in Healthy BM Samples (fig. 3d). No CD34-
positive agar colonies could be grown from healthy BM
samples, either before or after LAK cell coculture. LAK
cell coculture resulted in a significant reduction of CD15-
positive granulocyte colony counts (p ! 0.05, fig. 3d).
With cytokine preculture this reduction was less pro-
nounced (Cytok 1: p ! 0.05, Cytok 2: p ! 0.01, ISC/FCS:
p ! 0.001, fig. 3d).
Prognostic Value of LAK Cell Treatment in vitro
(fig. 4)
Statistical evaluations revealed that patients studied at
diagnosis, whose BM-MNC were pretreated with Cytok 1
and whose CD34-positive colonies were reduced by more
than 20% by autologous LAK cells in vitro (n = 8) had a
significantly better survival probability than cases with-
out such a reduction (n = 2) (fig. 4, p = 0.04). No signifi-
cant differences were found (data not shown) with other
cut-off percentages. Moreover, we could show that pa-
tients studied in complete remission, whose clonal gene
rearranged BM-DNA could be reduced by LAK cells in
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Fig. 3. Influence of LAK cells on autologous untreated (thawed) BM-MNC or BM-MNC precultured with cytokines
for 14 days (Cytok 1, Cytok 2, ISC/FCS). Percentages of CD34- or CD15-positive colonies before and after the
LAK/BM coculture. a AML at diagnosis (n = 10). b AML at relapse (n = 4). c AML in complete remission (n = 7).
d BM from healthy donors (n = 7).
compared to cases without such a reduction (p = 0.05,
data not shown).
Our data show that clonal and CD34-positive BM cells
or colonies can be reduced by coculturing with autologous
LAK cells. The cytotoxic effect of LAK cells on leukemic
cells can be improved if BM cells are precultured in Cytok
1 or Cytok 2. Moreover, our results have clinical rele-
vance: patients had a better prognosis if clonal cells or




















   
   
   
   
   
   
   
   
   
   
   





















218 Acta Haematol 2001;105:209–221 Walburg Braun/Gerhartz/Schmetzer
Fig. 4. Survival probability of AML patients at diagnosis (n = 10);
the proportions of CD34-positive colonies obtained after cytokine
treatment in vitro and coculture with autologous LAK cells could be
reduced by more (1) or less (2) than 20% in vitro.
Discussion
Clonogenic Assays Are an Appropriate Method to
Determine and Quantify Leukemic Cells
AML is a stem cell disease developing clonally but het-
erogeneously with respect to cell differentiation. Publica-
tions investigating surface marker expression in AML
have so far focused on uncultured cells [3] or on clonogen-
ic cells studied by cytotoxic tests [14], but to a lesser
extent on the analysis of in vitro colonies. In previous
work, our group has shown that leukemic colonies can be
identified both at diagnosis and during remission by the
expression of ‘early’ markers like CD34, CD20 and CD10
whereas late antigens (like CD15) are expressed both on
normal and leukemic colonies [4, 15]. This differentiation
between normal and leukemic cells was carried out at a
clonogenic level by immunophenotyping of agar colonies
in situ. With this method, the leukemic tumor load of
untreated BM samples as well as of BM cells after cyto-
kine treatment and/or LAK cell treatment was evaluated.
As in previous studies [4, 16, 17], we could again demon-
strate the presence of large amounts of CD34-positive
cells and agar colonies after 7 days of culture in the pres-
ence of GM-CSF in active stages of AML and low
amounts in remission. In previous experiments we could
also demonstrate that the amounts of leukemic agar colo-
nies are predictive of relapse [16]. CD34-positive agar col-
onies could also be detected in samples obtained from
patients in remission of AML, but not in samples from
healthy BM donors. As already shown, the persistence of
clonogenic leukemic cells can also be proved at the clonal
level by Southern blot analyses: clonal, gene-rearranged
cells can be detected regularly in remission of AML [5, 17,
18]. Moreover, the differentiation capacity of cells can be
estimated by evaluating the amounts of CD15-positive
granulocyte agar colonies: proportions of CD15-positive
cells or colonies were significantly higher in BM samples
obtained from healthy BM donors or in remission of AML
than in samples obtained at diagnosis or at relapse. It can
be concluded that the colony assay used here is an appro-
priate method to detect and quantify clonogenic leukemic
cells in the course of AML.
Cytokines Can Reduce but Not Eliminate Clonogenic
Leukemic Cells in AML in vitro
Recombinant human cytokines may provide a poten-
tially interesting new approach to the treatment of AML
[8, 19]. GM-CSF, IL-3 and G-CSF are known to be regula-
tors of proliferation of leukemic cells, although these and
other cytokines (IL-1, IL-4, IL-6) have been demonstrated
to be capable of stimulating leukemic cell growth too [8,
20]. Recombinant human SCF – alone or in combination
with other cytokines – can be used for the ex vivo expan-
sion of stem cells [7]. We could already demonstrate that
cytokine combinations like Cytok 1 or Cytok 2 can
increase the number of healthy, CD34-positive cells and
reduce that of clonal, leukemic cells in cases with AML in
vitro [10]. These data prove that CD34-positive cells in
AML are clonal cells, whereas CD34-positive cells from
healthy donors grown in cytokine cocktails are healthy,
nonclonal stem cells. Those cells could be retransfused to
patients after high-dose chemotherapy for an early recon-
stitution of the hematopoietic system [7]. The aim of this
study was to investigate the influence of SCF-containing
cytokine cocktails on the proliferation and differentiation
capability of leukemic and nonleukemic BM-MNC in
vitro. Moreover, the clinical significance had to be evalu-
ated. At diagnosis of AML reduction in leukemic cells and
colonies as well as induction of granulopoietic and lym-
phopoietic cell differentiation could be shown in all exam-
ined cases. At relapse of the disease, the effect of cytokine
treatment could only be demonstrated in 50% of the cases
which means that leukemic cells are more sensitive to
cytokine treatment at diagnosis than at relapse. This
might be explained by a different autocrine production of
cytokines by BM cells at relapse. IL-1ß and IL-6 are
known to be able to inhibit or stimulate AML blast prolif-
eration depending on the ‘history’ of the leukemic cells
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cells can differentiate – without losing their leukemic
signs. That could mean that a ‘preleukemic state’, but no
complete remission might be achieved by cytokine treat-
ment in vitro [10, 17, 22]. In complete remission, a reduc-
tion in CD34-positive colonies was achieved in all exam-
ined cases. In healthy BM, leukemic CD34-positive colo-
nies could never be detected. GM-CSF has been shown to
favor AML cell proliferation and healthy BM cell differ-
entiation [18]. The GM-CSF-containing medium (Cytok
1) was more effective in reducing the leukemic burden in
AML. This might be due to the additional tumor cyto-
toxic effect of GM-CSF [23]. Eradication of leukemic cells
could not be achieved by incubation of AML cells with
those cytokines. A reduction in clonogenic cells could also
be achieved (to a lower degree) by culturing cells in ISC/
FCS medium, which is probably due to unknown cyto-
kines in the FCS. Cytokine treatments as described here
have no negative influence on cell growth or viability of
BM-MNC. Addition of cytokines (Cytok 1, Cytok 2) to
the control medium (ISC/FCS) resulted in an increase in
single cell and colony absolute counts. Our results have
clinical significance. AML patients studied at diagnosis
survived longer, if clonal, CD34-positive cells or leukemic
colonies grown from BM-MNC in cytokine-containing
medium could be reduced by more than 50% in vitro [10].
Relapse-free survival times were significantly longer in
those patients in whom a reduction of CD34-positive cells
in vitro could be demonstrated.
We conclude that Cytok 1 and Cytok 2 are appropriate
cocktails to (1) expand healthy nonclonal CD34-positive
cells and (2) reduce clonogenic CD34-positive cells or col-
onies in AML, especially in remission of the disease. (3)
Our data have clinical significance: patients in whom a
reduction of the leukemic tumor load could be achieved
by cytokine treatment in vitro had a better survival proba-
bility.
LAK Cells Can Reduce, but Not Eliminate Clonogenic
Cells in AML
Cytotoxic mechanisms against tumor cells can be me-
diated by NK or LAK cells and can result in suppression
of leukemic cells [12]. However, the mechanisms of action
of those NK or LAK cells are not fully understood [24].
Cytotoxic cytokines released by NK, LAK or other cells or
adhesion molecules or histocompatibility antigens might
sensitize effector cells for the NK/LAK cell attack. Our
study was aimed at finding out whether leukemic progeni-
tors from AML patients can be reduced by autologous
LAK cells and whether the cytotoxic effect of LAK cells
can be improved by preincubation of BM-MNC with dif-
ferent cytokine cocktails. The potential cytotoxic effect of
LAK cells on untreated or precultured leukemic BM-
MNC was evaluated after coculture. Proportions of
CD34-positive BM agar colonies before and after LAK
cell coculture were evaluated and compared. Our data
showed that autologous LAK cells can reduce, but not
eliminate CD34-positive BM colonies obtained at active
stages of AML as well as in remission. This means that the
cytotoxic effect of LAK cells might be efficient in reduc-
ing residual leukemia, but that LAK cells are more or less
ineffective as the only cytotoxic agent at active stages of
AML, as already shown by others and ourselves [12, 25,
26]. This might be due to different expression of adhesion
molecules like CD54 or CD58 in active disease as com-
pared to remission [24, 27]. In complete remission, the
percentage of NK cells in BM decreases when relapse
occurs [28]. Preincubation of BM-MNC with cytokine
cocktails containing SCF, IL-1ß, IL-3, IL-6, EPO with/
without GM-CSF resulted in a more efficient reduction in
CD34-positive leukemic colonies by LAK cells compared
to results with not prestimulated BM cells. If the cytokine
cocktail (Cytok 1) contains GM-CSF, the antileukemic
effect of LAK cells seems to be better than that of cocktails
without GM-CSF (Cytok 2) as already described [12, 22,
27]. Preculturing cells in ISC/FCS as a control showed
that a reduction in clonogenic cells could also be achieved
(to a lower degree) by this medium, which is probably due
to cytokines in the FCS. Our data are of prognostic signifi-
cance: patients studied at diagnosis, whose BM cells were
pretreated with Cytok 1 and whose CD34-positive colo-
nies were reduced by more than 20% by autologous LAK
cells in vitro had a significantly better survival probability
as compared to cases without such a reduction. In prelimi-
nary experiments we could already show that the progno-
sis of AML patients was better if clonal, gene-rearranged
DNA could be reduced by autologous LAK cells in vitro
[12]. The advantage of measuring the antileukemic effect
of LAK cells by clonogenic assays and flow cytometric
estimation of CD34-positive cells as compared to 51Cr-
release assays [29] is that specific cells responsible for leu-
kemic proliferation, which survive also in remission, are
also picked up.
We conclude hat autologous LAK cells can reduce but
not eliminate leukemic colonies and this LAK cell effect
can be increased by coculture of BM effector cells with
cytokine cocktails like Cytok 1 or Cytok 2. This means
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Conclusion and Perspectives
Patients have 1012 malignant cells at diagnosis. In com-
plete remission there may still be as many as 1010 neoplas-
tic cells [30]. Therefore different techniques to study
‘minimal residual disease’ with the goal of identifying ear-
ly relapsing patients are under investigation. This in-
cludes cytogenetic techniques such as in situ hybridiza-
tion, polymerase chain reaction or immunophenotyping
[30–32]. Our results show that clonogenic assays com-
bined with immunophenotyping can be used to study
‘minimal residual disease’ in AML [4] and the persistence
or reemergence of leukemic progenitors by quantifying
the leukemic tumor load in the course of the disease. In
summary, our data show that (1) leukemic progenitors are
detectable in BM samples obtained at diagnosis and at
relapse as well as in complete remission of AML; (2) incu-
bation of BM-MNC with cytokine cocktails and/or autol-
ogous LAK cells leads to a reduction of the leukemic
tumor load; elimination of leukemic progenitors, how-
ever, could not be achieved; (3) BM-MNC are less suscep-
tible to cytokines or LAK cell treatment at relapse than at
diagnosis of AML. Clinical trials have been conducted to
investigate the ability of IL-2 to generate killer cells in
AML patients in vivo [33]. Because of the high incidence
of side effects, this therapy on its own is not safe. Addi-
tional malignant hematolymphoid disorders can be in-
duced by NK cells [34]. However, AML patients might
benefit from a LAK cell treatment in vivo, especially if
this treatment is combined with cytokines, although ad-
verse clinical effects such as stimulation of leukemic pro-
liferation might be induced [35]. Moreover, new cytokine
combinations (SCF, TPO, Flt-3-ligand) have to be tested
in order to reduce clonogenic leukemic cells in AML, for
example by in vitro purging of BM samples or for use in
vivo. Moreover, ‘priming’ effects of cytokines on the pro-
liferation of leukemic cells have to be evaluated [9]. In
addition, the generation of cytotoxic, NK-like effector
cells such as ‘cytokine-induced killer’ (CIK) cells or ‘ad-
herent LAK cells’ (A-LAKs) have to be stimulated and
studied in depth to learn about cell-cell contacts of AML
blasts with accessory cells and with cytotoxic effector cells
in the BM. First results point to a regulating and tumor-
suppressing role of NK cells in this direct or indirect cyto-
kine-mediated cytotoxicity [27]. Moreover, first clinical
and in vitro results demonstrate that histamine and IL-2
synergize to kill AML blasts in vitro and that prolonged
remission times could be achieved in 5 patients treated in
vivo [36]. Other data show that apoptotic death of AML
cells can be induced through fas/Apo-1 (CD95) mediated
cytotoxicity with the CD95 ligand expressed on IL-2-acti-
vated T cells [37].
In conclusion, these data demonstrate the important
role of LAK cells in the cytotoxic cascade against tumor
cells. Many problems have to be solved to find the most
cytotoxic ‘killer cells’, the best way of producing them in
vitro, the best activity confined to certain leukemia types
or to certain patients, the optimal clinical settings and the
optimal clinical outcomes. Nevertheless, we think that
our results can contribute important data for the develop-
ment of innovative strategies in the treatment of AML.
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